Alterity Holds A$41.3M After A$5.5M Option Proceeds; Phase 3 Start-Up Underway
ATHE is trading near its 52-week low of $2.01 (8.0% above the low) on light trading volume (0.2× avg).
Summary
Alterity ended the September quarter with A$41.3 million in cash after raising about A$5.5 million net from ATHO option exercises and collecting a A$3.98 million R&D tax refund, while quarterly operating burn was just A$1.34 million. Phase 3 start-up activities for ATH434 in MSA are underway, including manufacture of the first registration batch.
Key Events · Financing and Capital Events · ATHE
-
Cash Rises to A$41.3 Million
Cash and cash equivalents were A$41.3 million at 30 September 2026, up from A$37.3 million at the start of the quarter, including a A$3.98 million Australian R&D tax refund and roughly A$5.5 million net from ATHO option exercises.
-
Quarterly Burn Only A$1.34 Million
Net operating cash outflow was A$1.34 million for the quarter, which the Appendix 4C translates into an estimated 30.8 quarters of funding available at the current rate.
-
Option Underwriting Raised A$5.5 Million Net
3,191,983 ATHO options were exercised before expiry and 8,400,000 shortfall shares were issued under the MST Financial underwriting at A$0.50, raising about A$5.5 million after costs.
-
First Phase 3 Registration Batch Manufactured
Phase 3 operational activities have begun: protocol finalization, vendor selection, site identification and qualification, and manufacture of the first registration batch of ATH434 for the pivotal trial.
Analysis · ATHE · Life Sciences
The headline number is the cash: A$41.3 million at 30 September 2026, up from A$37.3 million three months earlier, after a quarter in which operating burn was only A$1.34 million. That combination — a small burn against a freshly topped-up balance — gives the company roughly 30.8 quarters of funding at the current rate, which is the difference between needing a dilutive raise to start Phase 3 and being able to fund the operational build-out on its own. The A$5.5 million net raised from the ATHO option exercise and underwriting, plus a A$3.98 million R&D tax refund, did the heavy lifting. Against that, the filing confirms the company is still running a structured process with external advisers on partnering and funding alternatives, so a deal remains a live possibility rather than a signed one. The clinical news in the release — FDA alignment on the Phase 3 design, the new composition of matter patent to 2045, and the 52% slowing of functional decline in the Phase 2 analyses — was already disclosed in the 23 September, 13 August and 5 October filings respectively; what is new here is that the first registration batch of ATH434 has been manufactured and site and vendor selection is underway.
How filings like this one have moved
In the 30 days to Oct 30, 2026, 30.7% of the 1581 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.02%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ATHE was trading at $2.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $41.9M. The 52-week trading range was $2.01 to $5.89. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.